Effect of selective heart rate slowing in heart failure with preserved ejection fraction [PDF]
, 2015 Background Heart failure with preserved ejection fraction (HFpEF) is associated with significant morbidity and mortality but is currently refractory to therapy.
Ashrafian, Houman +12 more
core +2 more sources
Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT [PDF]
, 2016 Aims In heart failure, non-adherence increases events; in turn, the effect of hospitalization on adherence is incompletely understood. We explored the relationship of non-adherence to outcomes, hospitalizations with non-adherence, and the influence of
Alosco +35 more
core +1 more source
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm [PDF]
, 2016 Many conditions culminate in heart failure (HF), a multi-organ systemic syndrome with an intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the forefront of ...
Abozguia +119 more
core +1 more source
Impact of heart rate on myocardial salvage in timely reperfused patients with STSegment elevation myocardial infarction. new insights from cardiovascular magnetic resonance [PDF]
, 2015 BACKGROUND: Previous studies evaluating the progression of the necrotic wave in relation to heart rate were carried out only in animal models of ST-elevated myocardial infarction (STEMI).
AGATI, Luciano +8 more
core +3 more sources
ESC Heart Failure, 2021 Aims Ivabradine has been used in patients who have chronic heart failure (HF) with reduced ejection fraction (HFrEF) and concomitant sinus heart rate ≥70 bpm. This administration for acute HFrEF remains a concern. This study used a real‐world multicentre
Chia‐Te Liao +9 more
doaj +1 more source
Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) trial [PDF]
, 2016 Background: Elevated resting heart rate (HR) and low systolic blood pressure (SBP) are related to poor outcomes in heart failure (HF). The association between visit-to-visit variation in SBP and HR and risk in HF is unknown. Methods and Results:
Borer, Jeffrey +8 more
core +1 more source
Budget impact of adding ivabradine to standard of care in patients with chronic systolic heart failure in the United States [PDF]
, 2016 BACKGROUND: Heart failure (HF) costs $21 billion annually in direct health care costs, 80% of which is directly attributable to hospitalizations. The SHIFT clinical study demonstrated that ivabradine plus standard of care (SoC) reduced HF-related and all-
Borer, Jeffrey S. +10 more
core +1 more source
Ivabradine Reduces Chemokine-Induced CD4-Positive Lymphocyte Migration
Mediators of Inflammation, 2010 Aims. Migration of CD4-positive lymphocytes into the vessel wall is a critical step in atherogenesis. Recent data suggest that ivabradine, a selective I(f)-channel blocker, reduces atherosclerotic plaque formation in apolipoprotein E-deficient mice ...
Thomas Walcher +6 more
doaj +1 more source
Indian Heart Journal, 2023 Objectives: Ivabradine may have a role in rate control of atrial fibrillation (AF) due to effects on HCN channels in AV node. We studied role of Ivabradine in rate control of rheumatic AF. Methods: 80 patients, rheumatic AF, HR > 100 bpm (age 47 ± 11 yrs,
Arpita Katheria +8 more
doaj +1 more source
Efficacy profile of ivabradine in patients with heart failure plus angina pectoris [PDF]
, 2016 Objectives: In the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT), slowing of the heart rate with ivabradine reduced cardiovascular death or heart failure hospitalizations among patients with systolic chronic heart ...
Borer, Jeffrey S. +9 more
core +1 more source